Ondine’s Dr. Nicolas Loebel receives IPA Lifetime Achievement Award for photodisinfection advancements
Vancouver, British Columbia, Canada – October 31, 2022
Nicolas Loebel, Nicolas Loebel, President &Chief Technology Officer at Ondine Biomedical Inc.
Dr. Nicolas Loebel, President and Chief Technology officer of Ondine Biomedical Inc., has been awarded the 2022 Lifetime Achievement Award by the International Photodynamic Association (IPA) at the annual Photodynamic Therapy and Photodiagnostic (PDT-PDD) Symposium in Nancy, France. The Lifetime Achievement Award recognizes Dr. Loebel’s significant contributions which have greatly advanced the emerging field of antimicrobial photodynamic therapy (aPDT), also known as photodisinfection.
Dr. Loebel’s research and development career spans over 20 years and has resulted in significant advancements in the science and clinical translation of aPDT, which is the foundation of Ondine Biomedical’s nasal photodisinfection technology, Steriwave™.
Dr. Loebel has been a leading force in the success of translating photodisinfection from bench to field, demonstrating safety, efficacy, and significant cost savings to healthcare systems. His pioneering work has led to numerous first-of-kind photodisinfection-based medical devices that prevent and treat multidrug-resistance infections without the use of antibiotics.
On behalf of his friends and colleagues at Ondine, we congratulate Nick for his well-deserved recognition.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as sinusitis, ventilator-associated pneumonia, burns, and other indications.
For Media Information
5654 & Company
